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Abstract: Ciclesonide is a novel corticosteroid which is optimized for topical use. It is a 
pro-drug which is activated locally in the airway mucosa, lipid-conjugated for local retention, 
and has very high protein binding in circulation leading to low systemic bioavailability. These 
characteristics should lead to highly selective activity with reduced local and systemic side 
effects. It has been established as an inhaled medication for asthma and has also been shown in 
double-blind trials to be efﬁ  cacious for the treatment of seasonal and perennial allergic rhinitis. 
However no data have yet demonstrated superiority over existing nasal topical corticosteroids, 
either in terms of efﬁ  cacy or adverse effects, and trials have not yet clearly shown efﬁ  cacy in 
rhinitis in children. Therefore the place of ciclesonide in the treatment of allergic rhinitis rela-
tive to other existing products remains unclear.
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Introduction
Allergic rhinitis is characterised by chronic inﬂ  ammation of the nasal membranes 
with symptoms including itching, sneezing, nasal congestion and rhinorrhoea. An 
estimated 1/5 of the population have allergic rhinitis, of which 40% have perennial 
allergic rhinitis and 40% have seasonal allergic rhinitis (Meltzer et al 2007). Allergic 
rhinitis has been shown to decrease quality of life in patients and places a burden on 
the health care system (Kim et al 2007).
Although accepted treatments for allergic rhinitis include antihistamines, deconges-
tants, anticholinergic agents, intranasal cromolyn and leukotriene receptor antagonists, 
intranasal corticosteroids are the most effective therapy for allergic rhinitis and ﬁ  rst-
line therapy in guidelines for moderate to severe disease (Ratner et al 2007). Allergen 
immunotherapy is also an effective treatment for certain patients with allergic rhinitis. 
Intranasal corticosteroids include mometasone furoate, beclomethasone diproprionate, 
ﬂ  uticasone propionate, ﬂ  uticasone furoate, triamcinolone acetonide, budesonide and 
ﬂ  unisolide (Herman 2007). With the exception of beclomethasone, these agents have 
been shown to have minimal systemic absorption and side effects and are quickly 
metabolized to less active metabolites (Herman 2007). In many countries, budesonide, 
ﬂ  uticasone, mometasone and triamcinolone are approved for once-daily dosing.
Ciclesonide description
Ciclesonide is a new-generation corticosteroid that has been developed for treatment 
of asthma and allergic rhinitis (Ratner et al 2006). Ciclesonide is administered as an 
inactive pro-drug and converted to active desisobutyryl-ciclesonide (des-CIC) in the 
upper and lower airways (Ratner et al 2006). In a rat lung model, des-CIC had 100-fold 
greater afﬁ  nity for the glucocorticoid receptor (GR) than the parent compound (Stoeck 
et al 2004). Human GR binding studies showed the same degree of afﬁ  nity conversion 
and furthermore demonstrated that the afﬁ  nity of des-CIC was similar to ﬂ  uticasone 
(Belvisi et al 2005). Metabolism of ciclesonide to the active form occurs through 
the activity of carboxylesterases and cholinesterases and has been demonstrated to Journal of Asthma and Allergy 2008:1 50
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occur in human nasal epithelial cells in vitro (Sato et al 
2007). Des-CIC undergoes reversible lipid conjugation and 
may serve as a reservoir of active drug, therefore leading to 
prolonged drug effect (Nave et al 2005). It seems that the 
conversion rate of ciclesonide to des-CIC is lower in oro-
pharygeal epithelium, which implies a selective activation in 
respiratory mucosa and therefore an increased corticosteroid 
effect in the nose (and lung, for the inhaled drug) relative to 
the oropharynx. This would be expected to lead to reduced 
steroid-related oropharyngeal and laryngeal side effects 
(hoarseness, candidiasis) compared to conventional inhaled 
corticosteroids, and indeed this is seen in clinical studies. 
Local conversion of ciclesonide to the active metabolite 
coupled with lipid conjugation and very high protein bind-
ing (Rohatagi et al 2005) may serve to limit the systemic 
corticosteroid effects of the drug; in preclinical studies (in 
rats) (Belvisi et al 2005), inhaled ciclesonide showed 44-fold 
reduced potency in inducing adrenal involution and 22-fold in 
causing femoral plate hypoplasia compared with ﬂ  uticasone 
propionate. Oral bioavailability was also shown to be lower 
relative to budesonide (Stoeck et al 2004).
Formulations of intranasal corticosteroids (INCS) contain 
preservatives to inhibit bacterial growth, and other additives 
to retard clearance of the drug and maintain appropriate mois-
ture levels. Marketing of INCS often focuses on differences 
between products that may be perceived as important in deter-
mining prescribing behavior. Both Ciclesonide and budesonide 
contain potassium sorbate as an inhibitor of bacterial growth. 
No adverse effects have been reported with the use of potas-
sium sorbate in INCS usage in humans. It does not alter ciliary 
beat frequency in in vitro studies of cultured human nasal 
mucosal cells (Hofmann et al 2004). Benzalkonium chloride 
(BKC) is utilized in all other INCS; data on the effect of BKC 
on nasal mucosa is controversial. In vitro studies have dem-
onstrated ciliotoxicity with BKC (Riechelmann et al 2004), 
however reviews of in vivo studies (Graf  2001; Marple et al 
2004) have reported no adverse effect on nasal mucociliary 
clearance or ciliary beat frequency. There has been one report 
(Naclerio et al 2003) of a decrease in nasal clearance between 
treatment groups in a 2-week in vivo study of budesonide (no 
BKC) vs mometasone furoate (contains BKC) nasal spray.
Most INCS (except ciclesonide) contain thixotropic agents 
such as carboxymethylcellulose to confer high viscosity and 
delay mucosal clearance. These sprays need to be shaken 
before use to induce shearing forces to decrease viscosity, 
hence enabling the spray to be administered as a mist. It is not 
known whether failure to shake the bottle prior to use impairs 
nasal mucosal distribution and hence effectiveness. In contrast, 
ciclesonide is presented to the nasal mucosa in a hypotonic 
suspension (Meltzer 2007). Diffusion of water molecules from 
the hypotonic solution into the nasal mucosa increases viscos-
ity, delays clearance and hence increases local concentration 
and absorption of ciclesonide into the nasal mucosa. There is 
no evidence that the delay in mucosal clearance that occurs 
with a hypotonic solution offers a clinical advantage over 
isotonic ICNS formulations containing thixotropic agents. 
Importantly however, in an in vitro study (Pujara et al 1995) 
hypotonic solutions induced lactate dehydrogenase release 
from the rat nasal cavity – a surrogate marker of cell leaching or 
cell lysis. Ciliary beat frequency does not seem to be impaired 
in in vitro studies of human nasal mucosa with hypotonic 
solutions; however similar studies have not been performed in 
allergic rhinitis, and importantly, not with ciclesonide.
Efﬁ  cacy
Ciclesonide has been shown to be effective for treatment of 
both seasonal and perennial allergic rhinitis. In a placebo-
controlled study of 471 patients ciclesonide 200 μg has 
demonstrated a signiﬁ  cant reduction in both instantaneous 
and reﬂ  ective morning and evening total nasal symptom 
scores (TNSS) in groups with moderate perennial allergic 
rhinitis (Meltzer et al 2007). Improvement was made in all 
four domains of the TNSS – runny nose, itching, sneezing 
and nasal congestion. Furthermore in a study of 701 patients 
with moderate seasonal allergic rhinitis, ciclesonide at a 
dose of 100 μg and 200 μg has been shown to decrease sum 
morning and evening reﬂ  ective TNSS; however the greater 
dose was associated with a larger improvement in symptom 
score (Ratner et al 2006). In a placebo-controlled study of 
24 patients, ciclesonide has also been shown to increase 
nasal airﬂ  ow signiﬁ  cantly when measured by anterior rhino-
manometry – 30% increase after 1 week of ciclesonide 200 μg 
daily (Schmidt et al 1999). In a long-term trial of 663 patients 
to assess the safety of ciclesonide, there was no evidence of 
tachyphylaxis (Chervinsky et al 2007). There are few studies 
directly comparing the efﬁ  cacy of intranasal corticosteroids, 
and head to head studies designed to assess efﬁ  cacy have 
not been published (Herman 2007). Of comparison studies 
published, most have found similar efﬁ  cacy between INCS 
for allergic rhinitis; however there is some evidence that 
budesonide has superior efﬁ  cacy to ﬂ  uticasone in the treat-
ment of seasonal allergic rhinitis (Herman 2007).
Safety and adverse effects
Ciclesonide has several pharmacokinetic attributes that are 
desirable from a safety perspective. It has low systemic Journal of Asthma and Allergy 2008:1 51
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bioavailability (1%), rapid clearance (elimination half-life 
of 3.5 hours) and a highly protein bound active metabolite 
(99%) (Nave et al 2006). These features decrease systemic 
absorption and hence risk for adverse effects. In one phar-
macokinetics study (Nave et al 2006), 48 subjects were 
randomized to 6 groups with a daily dose of 50, 100, 200 and 
400 μg (od) and 400 μg bid ciclesonide. One subject in the 
400 μg OD and one in the 400 μg bid group showed levels 
of ciclesonide greater than 25 pg/mL – the lower limit of 
quantiﬁ  cation (LLOQ). For des-CIC, the majority of samples 
were below the LLOQ (10 pg/mL); however in the 400 μg 
bd group, 7 out of 324 samples were above 20 pg/mL. Also, 
there was no decrease in serum free cortisol levels compared 
with placebo and there was maintenance of diurnal variation 
in cortisol in those treated with ciclesonide. Although there 
was a decrease in urinary free cortisol, the decrease occurred 
in both the ciclesonide and placebo group with no signiﬁ  cant 
difference between these groups. In a study of 471 patients 
(Meltzer et al 2007), 238 of which were treated with intrana-
sal ciclesonide 200 μg daily and 233 with placebo, adverse 
effects were reported at a similar rate between ciclesonide 
and placebo group (102 vs 110). Long term data was reported 
in a 12 month randomised controlled trial of ciclesonide in 
patients with PAR greater than 12 years of age (Chervinsky 
et al 2007). 441 patients were assigned to 200 μg ciclesonide 
daily and 222 were assigned to placebo. Reported adverse 
events were similar in the treatment group and control group 
(75.1% vs 74.3%) and of similar frequency to those reported 
for other INCS. Epistaxis, pharyngolaryngeal pain and 
sinusitis were higher in the treatment group however there 
was increased nasopharyngitis and upper respiratory tract 
infection in the placebo group.
All INCS result in an increase in the frequency of epi-
staxis compared with the use of placebo. Epistaxis is one of 
the more common adverse effects encountered clinically and 
may result in cessation of INCS use. Duration of use, method 
of administration, ascertainment criteria and daily dose are 
important determinants of this adverse effect. Ciclesonide 
at a dose of 200 μg once daily for 48 weeks resulted in a 
rate of epistaxis of 10% compared to 7.2% in the placebo 
group (Sato et al 2007). In a 6-week trial, this dose was 
associated with a rate of epistaxis of 7.6% compared to a 
placebo group of 5.2% (Meltzer et al 2007). The prescrib-
ing information for other INCS demonstrates an increase 
in epistaxis over placebo; however the rates of epistaxis 
of both groups of subjects for the various INCS are much 
lower than reported for ciclesonide. It is important to note 
that the prescribing information for ﬂ  uticasone propionate 
(Flixonase Nasal Drops) at a dose of 400 μg identiﬁ  es a rate 
of epistaxis of 19% compared with 4% in the placebo group 
(in the treatment of sinonasal polyposis). Intriguingly, at a 
dose of ﬂ  uticasone propionate 400 μg bd in another study 
of nasal polyposis, the rate of epistaxis was only 6%, with 
a rate of 4% in the placebo group. This illustrates the dif-
ﬁ  culty in comparing data from one trial to another, even 
when using the same INCS. Head to head studies for given 
indications of use are needed to clarify not only efﬁ  cacy, 
but also the relative frequency of the more common adverse 
events. Uncommon adverse events such as septal perforation 
are likely to be reported only in the post-marketing period. 
There are no reports of septal perforation with the use of 
ciclesonide for allergic rhinitis, but any report of epistaxis 
from a patient using an INCS should alert the clinician to 
the possibility of signiﬁ  cant mucosal ulceration/atrophy. The 
chronic administration of topical steroids is well recognized 
to result in atrophy of epithelial surfaces, and concern has 
been expressed that mucosal atrophy might arise with the 
long-term use of INCS; evidence for this is lacking, yet 
concern at the possibility of the development of atrophy has 
possibly resulted in a degree of overcautiousness in dose and 
duration of treatment with INCS. Histopathological studies 
of nasal mucosa before and after long term INCS usage has 
not been reported for ciclesonide, however nasal mucosal 
biopsies before and after 12 months of mometasone furoate 
200 μg/day did not reveal any changes of atrophy or epithelial 
thickness, but showed a reduction of the inﬂ  ammatory cell 
inﬁ  ltrate and a decrease in focal metaplasia (Minshall et al 
1998), and biopsies after 2 to 5 years of continuous treatment 
with budesonide also did not show any deleterious change 
(Pipkorn et al 1988). Further studies at higher doses for all 
of the INCS in a variety of disorders are needed to enable 
clinicians to conﬁ  dently use this class of medications to their 
fullest potential.
Severe adverse events were found to be increased in 
the ciclesonide group compared with placebo (13.4% vs 
11.7%), but these were not considered to be related to the 
active medication (Chervinsky et al 2007). Importantly, in 
terms of systemic adverse events, there was no decrease 
from baseline or signiﬁ  cant difference between the two 
groups in 24-hour urinary cortisol level or morning plasma 
cortisol levels at 24 or 48 weeks (Chervinsky et al 2007) of 
ciclesonide 200 μg daily. An absence of adrenal suppression 
has also been reported for budesonide, triamcinolone and 
mometasone (Wilson et al 1998). Importantly, the use of 
betamethasone nasal drops has been reported to affect growth 
(Daman Willems et al 1994; Skoner et al 2000), although the Journal of Asthma and Allergy 2008:1 52
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later study did not have age or height controls. No studies 
have examined growth velocity in children treated with nasal 
ciclesonide; however an inhaled dose of 160 mg daily (to 
treat asthma) in children aged 4 to 11 years did not show any 
modiﬁ  cation of adrenal function (Gelfand et al 2006) or any 
signiﬁ  cant change in growth of children aged 5 to 8 over a 
period of 1 year (Skoner et al 2008). The possible increase 
in incidence of cataracts and/or glaucoma in association with 
the use of intranasal corticosteroids remains controversial. 
Ciclesonide used regularly for 1 year in 318 subjects was 
not associated with any increase intraocular pressure or 
cataract development compared with placebo (156 subjects) 
(Chervinsky et al 2007).
Considering that allergic rhinitis often occurs in patients 
with asthma, safety when used in combination with standard 
asthma therapy is an important consideration. In a random-
ized, double-blind, placebo- and active-controlled non-
inferiority trial, patients aged 18 to 60 years with asthma and 
SAR were commenced on a 10 day run-in period of inhaled 
beclomethasone dipropionate 320 μg twice daily and com-
menced on a 43 day period of either intranasal ciclesonide 
200 μg or placebo and at the conclusion of this period 
were given 2 mg of dexamethasone. Fifty-six patients were 
assigned to ciclesonide and 55 were treated with placebo, and 
although plasma cortisol (AUC0–24 h) decreased signiﬁ  cantly 
in the 10-day run-in period of inhaled beclomethasone and 
intranasal placebo, there was no signiﬁ  cant suppression 
between the placebo and the ciclesonide group at the end 
of the trial period. A decrease in plasma cortisol after being 
given dexamethasone the day following the completion of 
the ciclesonide or placebo period demonstrated that further 
inhibition of the HPA axis was indeed possible (Ratner et al 
2007). In a similarly structured study in which asthma was 
treated with inhaled ﬂ  uticasone–salmeterol 500/50 μg, cicle-
sonide did not add to cortisol suppression (Kim et al 2007).
Tolerability
Perception of taste, anterior and posterior nasal dripping of 
spray, and smell are important criteria in patient preference 
for the use of INCS (Mahadevia et al 2004). BKC has an 
unpleasant bitter taste; budesonide (which does not contain 
BKC) was preferred over ﬂ  uticasone propionate on the 
basis of taste (Shah et al 2003), and similarly, triamcinolone 
acetonide was preferred over ﬂ  uticasone propionate and 
mometasone furoate (Bachert et al 2002). Studies of cicle-
sonide nasal spray have shown no difference to placebo in 
parameters of tolerability such as local irritation (Meltzer 
et al 2007) or discomfort (Chervinsky et al 2007), but taste 
and smell and other subjective patient preference aspects 
were not reported.
Discussion
In a meta-analysis of the efﬁ  cacy of the treatment of allergic 
rhinitis, INCS were shown to have a clear beneﬁ  t over oral 
antihistamines in relieving nasal symptoms (Weiner et al 
1998). Ciclesonide is a novel corticosteroid distinguished 
by the requirement for conversion from a relatively inac-
tive pro-drug to a potent agent in the mucosa of the target 
organ, the formation of lipid conjugates leading to prolonged 
duration of effect, and high protein binding and ﬁ  rst-pass 
metabolism leading to very low systemic absorption when 
used topically. These features would be expected in theory 
to increase activity of the drug in the target therapeutic area 
relative to the areas responsible for adverse effects such 
as the oropharyngeal mucosa and the systemic circulation. 
However even if these theoretical advantages were borne out 
in vivo, it is clear that they are most relevant to the inhala-
tion of corticosteroids to treat asthma, where large doses are 
delivered to a large area of mucosal epithelium and there 
is great exposure of the oropharynx during the inhalation 
procedure. By comparison, when topical corticosteroids are 
used to treat rhinitis the dose is low and there is minimal 
exposure of the oropharynx, such that candidiasis is very 
rare as a side effect even with existing agents.
The distinguishing features of the formulation of cicle-
sonide nasal spray are the hypotonic solution and the use 
of potassium sorbate (rather than the more common BKC) 
as a preservative. It is suggested that the former feature 
may enhance local concentration and absorption, which 
should increase efﬁ  cacy. The lack of BKC may reduce 
ciliary toxicity (although this is controversial) and improve 
tolerability.
Although corticosteroids are proven to be more effec-
tive than oral antihistamines for the treatment of allergic 
rhinitis, there is in contrast no convincing evidence that any 
INCS is more effective than any other (Waddell et al 2003). 
Several trials have compared some of the available INCS 
but no published studies have compared ciclesonide with 
any other INCS. The magnitude of effect of ciclesonide has 
been reported to be comparable to that previously reported 
for mometasone (Ratner et al 2006). Clearly there is a need 
for head to head studies of the various INCS not only to 
compare efﬁ  cacy, but also local and systemic adverse effects 
and nasal tolerability. Based on currently available trials there 
is no evidence that the unique pharmacological features of 
ciclesonide increase its efﬁ  cacy in comparison with other Journal of Asthma and Allergy 2008:1 53
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available nasal topical corticsteroids, and at this stage it 
would not seem to offer any clear clinical advantage.
Trials of other INCS have demonstrated efﬁ  cacy in other 
related parameters such as ocular symptoms and quality of 
life; these are not yet available for ciclesonide. Some forms 
of chronic rhinosinusitis and particularly nasal polyposis are 
corticosteroid responsive and topical corticosteroids have a 
demonstrated role in these conditions, but once again this 
effect has not yet been demonstrated for ciclesonide. Fur-
ther trials in these areas are awaited. It is possible that the 
maximum efﬁ  cacy of topical corticosteroids has already been 
achieved; in many patients regular use provides major and 
even total symptom relief. However a signiﬁ  cant proportion, 
particularly those with more complex disease (nasal polypo-
sis, chronic rhinosinusitis), remain symptomatic despite max-
imal doses of any topical drug. In these cases the limitations 
to efﬁ  cacy may have more to do with the system of delivery 
than the drug. It is known that oral (systemically delivered) 
corticosteroids can be of major beneﬁ  t in these conditions 
(Hissaria et al 2006) but clearly are not safe for long-term 
treatment. It is possible that different delivery systems such 
as drops instilled in the head-inverted position may improve 
efﬁ  cacy but comparative trials have not been done.
In summary, several novel features distinguish ciclesonide 
from existing INCS, including characteristics of the drug 
itself and of its formulation. Although these features may 
theoretically enhance the safety of the product, there has as 
yet been no conclusive demonstration that this translates to 
actual clinically important safety beneﬁ  t. The theoretical safety 
advantages of ciclesonide would appear to be more relevant to 
the treatment of asthma than rhinitis. Although there are as yet 
no direct comparisons of ciclesonide with other INCS, there 
does not appear to be indication from the existing studies that 
it is likely to be more efﬁ  cacious than other INCS, and there 
remains doubt about its efﬁ  cacy in children. Issues such as cost 
effectiveness, patient choice, licensing and regulation as well as 
ultimate determination of efﬁ  cacy and safety relative to existing 
products may eventually determine the place of ciclesonide in 
the therapeutic armamentarium and in the marketplace.
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